Neoadjuvant Immune Checkpoint Blockade: A Window into Treatment Response and Pri

• Neoadjuvant (pre-surgical) immune checkpoint blockade may prevent cancer relapse and progression.
• This treatment approach is now FDA-approved for resectable triple-negative breast cancer, and hundreds of clinical trials in other cancers are ongoing.
• Surgical resection specimens collected after several weeks of neoadjuvant ICB offer vast opportunities for predictive biomarker discovery and understanding ICB response/resistance.

Suzanne Topalian, MD, Associate Director / Professor of Surgery, Bloomberg~Kimmel Institute for Cancer Immunotherapy / Johns Hopkins University

Learn more about the IO360° Summit at www.io360summit.com